|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
27
|
|
pubmed:dateCreated |
2009-10-2
|
|
pubmed:abstractText |
To assess the maximum-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of intravenous (IV) irinotecan when administered together in children with refractory solid tumors. To assess the effect of gefitinib on the pharmacokinetics of IV irinotecan and on the bioavailability of a single oral dose of irinotecan.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:CrewsKristine RKR,
pubmed-author:DawNajat CNC,
pubmed-author:FurmanWayne LWL,
pubmed-author:GajjarAmar JAJ,
pubmed-author:HoughtonPeter JPJ,
pubmed-author:McCarvilleM BethMB,
pubmed-author:McGregorLisa MLM,
pubmed-author:NavidFaribaF,
pubmed-author:PanettaJohn CJC,
pubmed-author:Rodriguez-GalindoCarlosC,
pubmed-author:SantanaVictor MVM,
pubmed-author:SpuntSheri LSL,
pubmed-author:StewartClinton FCF,
pubmed-author:WuJianrongJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4599-604
|
|
pubmed:dateRevised |
2010-9-21
|
|
pubmed:meshHeading |
pubmed-meshheading:19687340-Administration, Oral,
pubmed-meshheading:19687340-Adolescent,
pubmed-meshheading:19687340-Antineoplastic Agents,
pubmed-meshheading:19687340-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:19687340-Biological Availability,
pubmed-meshheading:19687340-Camptothecin,
pubmed-meshheading:19687340-Child,
pubmed-meshheading:19687340-Child, Preschool,
pubmed-meshheading:19687340-Drug Synergism,
pubmed-meshheading:19687340-Female,
pubmed-meshheading:19687340-Humans,
pubmed-meshheading:19687340-Infant,
pubmed-meshheading:19687340-Infusions, Intravenous,
pubmed-meshheading:19687340-Male,
pubmed-meshheading:19687340-Neoplasms,
pubmed-meshheading:19687340-Protein Kinase Inhibitors,
pubmed-meshheading:19687340-Protein-Tyrosine Kinases,
pubmed-meshheading:19687340-Quinazolines,
pubmed-meshheading:19687340-Toxicity Tests,
pubmed-meshheading:19687340-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
|
|
pubmed:affiliation |
Department of Oncology, St Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105-3678, USA. wayne.furman@stjude.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
